FDA advisers vote 8-6 Friday to recommend the agency grant accelerated approval to Sarepta Therapeutics Inc.’s gene therapy for Duchenne muscular dystrophy.
You are here: Home / Top Stories / : FDA advisers narrowly back accelerated approval of Sarepta gene therapy